Sunshine Biopharma gets Nasdaq bid-price extension to Aug 26, 2024

Sunshine Biopharma Inc.

Received Nasdaq Hearings Panel exception until August 26, 2024 to regain minimum bid price compliance.
Must achieve closing bid price of at least $1.00 for 10 consecutive business days by deadline.
Company was previously notified of deficiency under Listing Rule 5550(a)(2).
Failure to meet conditions may result in delisting from Nasdaq.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.